Jeffrey E Rubnitz

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. pmc Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer 119:2061-6. 2013
  2. pmc Treatment outcome in older patients with childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 118:6253-9. 2012
  3. pmc How I treat pediatric acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 2794, USA
    Blood 119:5980-8. 2012
  4. pmc Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, TN 38105 2794, USA
    Lancet Oncol 11:543-52. 2010
  5. doi request reprint Acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Hematol Oncol Clin North Am 24:35-63. 2010
  6. pmc NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 2794, USA
    J Clin Oncol 28:955-9. 2010
  7. ncbi request reprint Baseline mannose binding lectin levels may not predict infection among children with leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:866-8. 2008
  8. pmc Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 113:5083-9. 2009
  9. ncbi request reprint Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 101:1677-84. 2004
  10. ncbi request reprint Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Pediatr Blood Cancer 44:138-41. 2005

Detail Information

Publications95

  1. pmc Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer 119:2061-6. 2013
    ..However, the impact of ALC relative to that of other prognostic factors on the outcome of children with acute lymphoblastic leukemia (ALL) treated in recent trials is unknown...
  2. pmc Treatment outcome in older patients with childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 118:6253-9. 2012
    ..To the authors' knowledge, the impact of age relative to that of other prognostic factors on the outcome of patients treated in recent trials is unknown...
  3. pmc How I treat pediatric acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 2794, USA
    Blood 119:5980-8. 2012
    ..The development of molecularly targeted agents, some of which are already in clinical trials, holds great promise for the future...
  4. pmc Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, TN 38105 2794, USA
    Lancet Oncol 11:543-52. 2010
    ....
  5. doi request reprint Acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Hematol Oncol Clin North Am 24:35-63. 2010
    ....
  6. pmc NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 2794, USA
    J Clin Oncol 28:955-9. 2010
    ..We propose to further investigate the efficacy of KIR-mismatched NK cells in a phase II trial as consolidation therapy to decrease relapse without increasing mortality in children with AML...
  7. ncbi request reprint Baseline mannose binding lectin levels may not predict infection among children with leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:866-8. 2008
    ..Additional studies are required to determine whether serial MBL measurements may be valuable for this purpose...
  8. pmc Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 113:5083-9. 2009
    ..We also suggest that hematopoietic stem cell transplantation is often not required for cure of these patients...
  9. ncbi request reprint Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 101:1677-84. 2004
    ..Despite improvements in supportive care, death due to treatment toxicity remains a significant problem for children treated for acute leukemia...
  10. ncbi request reprint Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Pediatr Blood Cancer 44:138-41. 2005
    ..We therefore sought to determine if detection of relapse by blood counts before the onset of symptoms provided any clinical benefit...
  11. doi request reprint Childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, 332 N Lauderdale Street, Memphis, TN 38105 2794, USA
    Curr Treat Options Oncol 9:95-105. 2008
    ..More important, we must develop alternative treatment approaches, such as agents that target specific leukemia-associated abnormalities and agents that selectively eradicate leukemic stem cells...
  12. pmc Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial
    J E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 23:1410-6. 2009
    ..For all patients, 5-year event-free survival and overall survival estimates were 44.1+/-5.4 and 50.0+/-5.5%. Our results suggest that cladribine in combination with continuous-infusion cytarabine is effective therapy for childhood AML...
  13. ncbi request reprint Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study
    Jeffrey E Rubnitz
    Department of Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105 2794, USA
    J Clin Oncol 26:2186-91. 2008
    ..To prospectively determine the prognostic significance of the TEL-AML1 fusion in children with acute lymphoblastic leukemia (ALL)...
  14. doi request reprint Acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Pediatr Clin North Am 55:21-51, ix. 2008
    ....
  15. ncbi request reprint Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 48:10-5. 2007
    ..The association between race and outcome of treatment for childhood acute myeloid leukemia (AML) has not been adequately studied...
  16. ncbi request reprint Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 109:157-63. 2007
    ..Outcome after recurrence of childhood acute myeloid leukemia (AML) is poor. We performed this study to identify prognostic factors for recurrence and for survival after recurrence of AML...
  17. ncbi request reprint Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Mail Stop 260, 332 N Lauderdale Street, Memphis, TN 38105 2794, USA
    Leuk Res 28:349-52. 2004
    ..Despite the efficacy of the cladribine and cytarabine regimen in treating newly diagnosed acute myeloid leukemia (AML) in a previously reported study, the combination was not effective for relapsed or refractory childhood AML...
  18. ncbi request reprint Molecular diagnostics in the treatment of childhood acute lymphoblastic leukemia
    J E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital and University of Tennessee, College of Medicine, Memphis, TN 38105 2794, USA
    J Biol Regul Homeost Agents 14:182-6. 2000
    ..Molecular techniques are also used to detect minimal residual disease and genetic polymorphisms that are important in optimizing drug therapy...
  19. ncbi request reprint Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia
    Jeffrey E Rubnitz
    Department of Haematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Cancer Treat Rev 29:31-44. 2003
    ..In addition, gene expression profiling may improve the genetic classification of leukaemia and identify clinically important subgroups. It may also lead to the identification of new targets for novel antileukaemic agents...
  20. ncbi request reprint Molecular diagnostics in the treatment of leukemia
    J E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Curr Opin Hematol 6:229-35. 1999
    ..Several novel therapeutic agents targeted to molecular lesions of leukemic cells are under investigation...
  21. ncbi request reprint Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation
    J E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, The University of Tennessee College of Medicine, Memphis 38105 2794, USA
    J Clin Oncol 17:191-6. 1999
    ..To determine the molecular characteristics, clinical features, and treatment outcomes of children with acute lymphoblastic leukemia (ALL) and the t(11;19)(q23,p13.3) translocation...
  22. pmc Treating childhood acute lymphoblastic leukemia without cranial irradiation
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 360:2730-41. 2009
    ..Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse...
  23. ncbi request reprint Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia
    Elaine Coustan-Smith
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Br J Haematol 123:243-52. 2003
    ..022); overt recurrence of AML within the subsequent 6 months was significantly more likely in the former group. The assay described here holds promise for guiding the choice of post-remission treatment options in children with AML...
  24. pmc Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, MS 260, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 3678, USA
    J Clin Oncol 30:3625-32. 2012
    ..Response can now be assessed by minimal residual disease (MRD) monitoring with flow cytometry or polymerase chain reaction (PCR). We determined the relation among the results of these approaches and their prognostic value...
  25. ncbi request reprint Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 104:2690-6. 2004
    ..01% or more at the end of the 6-week remission induction phase. Our results suggest the efficacy of early intensification of intrathecal chemotherapy and provide the basis for studies omitting cranial irradiation altogether...
  26. ncbi request reprint Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia
    Sima Jeha
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee
    Cancer 120:1514-9. 2014
    ..To date, no data are available on the impact of TKIs on minimal residual disease (MRD) at the end of induction therapy among patients who have a poor early response to 2 weeks of induction therapy that does not include TKIs...
  27. ncbi request reprint Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia
    Elaine Coustan-Smith
    Departments of Hematology Oncology, Biostatistics, and Pathology, St Jude Children s Research Hospital, and the University of Tennessee, Memphis TN 38105 2794, USA
    Blood 100:2399-402. 2002
    ..007). These results indicate that peripheral blood may be used to monitor MRD in patients with T-lineage ALL and that peripheral blood MRD may provide strong prognostic information in patients with B-lineage ALL...
  28. ncbi request reprint Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:7936-41. 2005
    ..Our goal was to use the information to further refine therapy and advance cure rates...
  29. pmc Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:3293-300. 2011
    ..To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in children with relapsed/refractory leukemia...
  30. pmc Improved prognosis for older adolescents with acute lymphoblastic leukemia
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:386-91. 2011
    ..We reviewed the outcome of older adolescents (age 15 to 18 years) treated in four consecutive Total Therapy studies to determine if recent improved treatment extended to this high-risk group...
  31. ncbi request reprint Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia
    Carol O'Hear
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
    Cancer 119:4036-43. 2013
    ..However, to the best of the authors' knowledge, the effects of GO on levels of minimal residual disease (MRD) are unknown...
  32. pmc Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale St, Memphis, TN 38105 2794, USA
    Blood 108:3997-4002. 2006
    ..Further, the systemic clearance of methotrexate, teniposide, etoposide, and cytarabine did not differ with BMI (P > .3). We conclude that BMI does not affect the outcome or toxicity of chemotherapy in this patient population with ALL...
  33. ncbi request reprint Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 20:4217-24. 2002
    ....
  34. pmc Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia
    Sima Jeha
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Blood 108:3302-4. 2006
    ..9% versus 78% +/- 3.1% (P = .08). These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens...
  35. pmc High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia
    Wing Leung
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 118:223-30. 2011
    ..10; P = .01) at the time of transplantation. We concluded that transplantation has improved over time and should be considered for all children with very high-risk leukemia, regardless of matched donor availability...
  36. pmc Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
    Elaine Coustan-Smith
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet Oncol 10:147-56. 2009
    ..We studied leukaemic cells, collected at diagnosis, to identify cases with ETP features and determine their clinical outcome...
  37. pmc RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients
    Xueyuan Cao
    Department of Biostatistics, St Jude Children s Research Hospital, Memphis, TN, USA
    Pharmacogenomics 14:1449-66. 2013
    ..Ribonucleotide reductase catalyzes an essential step in the cellular production of deoxyribonucleotide triphosphates and has been associated with clinical outcome in cancer patients receiving nucleoside analog-based chemotherapy...
  38. ncbi request reprint Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia
    Elaine Coustan-Smith
    Department of Hematology Oncology, St Jude Children s Research Hospital and the University of Tennessee, Memphis, TN 38105, USA
    Blood 100:52-8. 2002
    ..Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome...
  39. ncbi request reprint Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia
    Jessica R Roberson
    Department of Hematology Oncology, St Jude Children s Research Hospital, and the University of Tennessee College of Medicine, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:542-8. 2008
    ..The percentage of myeloperoxidase (MPO)-positive blast cells is associated with prognosis in adult acute myeloid leukemia (AML), but this association is unsubstantiated in pediatric AML...
  40. pmc Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer 116:98-105. 2010
    ..The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed...
  41. ncbi request reprint Results of therapy for acute lymphoblastic leukemia in black and white children
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 290:2001-7. 2003
    ..Treatment results for acute lymphoblastic leukemia (ALL) clearly have improved over the past decade, but black children have not fared as well as white children in large national trials...
  42. ncbi request reprint Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome
    Susana C Raimondi
    Department of Pathology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer Genet Cytogenet 169:50-7. 2006
    ..16 can be included in the low-risk arm of treatment protocols. We cannot make similar recommendations for patients with T-lineage ALL because of the small number of cases (n = 3) in this study...
  43. pmc Minimal residual disease quantitation in acute myeloid leukemia
    David Shook
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Clin Lymphoma Myeloma 9:S281-5. 2009
    ..Other clinically informative uses of MRD testing include the detection of early relapse and the evaluation of the efficacy of new antileukemic agents...
  44. ncbi request reprint Favorable impact of the t(9;11) in childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 20:2302-9. 2002
    ..To determine the impact of MLL rearrangements on the outcome of children with acute myeloid leukemia (AML)...
  45. pmc Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
    Cancer 120:1985-92. 2014
    ..Intensive chemotherapy for pediatric acute myeloid leukemia incurs the risk of infectious complications, but the benefits of antibiotic prophylaxis remain unclear...
  46. pmc Ontogeny and sorafenib metabolism
    Eric I Zimmerman
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 18:5788-95. 2012
    ..To investigate the role of ontogeny in sorafenib metabolism to the equipotent active metabolite sorafenib N-oxide...
  47. ncbi request reprint Gene expression profiling of pediatric acute myelogenous leukemia
    Mary E Ross
    Department of Hematology Oncology, Hartwell Center for Bioinformatics and Biotechnology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Blood 104:3679-87. 2004
    ..Surprisingly, AMLs containing partial tandem duplications of MLL failed to cluster with MLL chimeric fusion gene cases, suggesting a significant difference in their underlying mechanism of transformation...
  48. pmc Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 30:2005-12. 2012
    ..Treatment outcome for black patients with cancer has been significantly worse than for their white counterparts. We determined whether recent improved treatment had narrowed the gap in outcome between black and white pediatric patients...
  49. pmc Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 117:1313-20. 2011
    ..However, the optimal G-CSF dosage for patients with AML has not been determined. To the authors' knowledge, G-CSF dosages have not been compared in a randomized AML study...
  50. ncbi request reprint Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 297:1207-15. 2007
    ..Little is known about the incidence of secondary neoplasms after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic leukemia...
  51. pmc Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia
    Sharyn D Baker
    Authors Affiliations Departments of Pharmaceutical Sciences, Structural Biology, Pathology, and Oncology, Hartwell Center for Bioinformatics and Biotechnology, St Jude Children s Research Hospital and Department of Pediatrics, University of Tennessee, Memphis, Tennessee
    Clin Cancer Res 19:5758-68. 2013
    ....
  52. pmc Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia
    Jassada Buaboonnam
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 3678, USA
    Pediatr Blood Cancer 60:1161-4. 2013
    ..The efficacy of combination chemotherapy with methotrexate (MTX) and asparaginase is not well known in relapsed and refractory acute leukemia after contemporary therapy...
  53. pmc Effect of body mass index on the outcome of children with acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 118:5989-96. 2012
    ..The effect of body mass index (BMI) on the treatment outcomes of children with acute myeloid leukemia (AML) is unclear and needs further evaluation...
  54. pmc Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia
    Wing Leung
    Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105 2794, USA
    Blood 120:468-72. 2012
    ..Although MRD before HCT is a strong prognostic factor, its impact has diminished and should not be regarded as a contraindication for HCT...
  55. ncbi request reprint Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia
    Scott C Howard
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    JAMA 288:2001-7. 2002
    ..Traumatic or bloody lumbar puncture (LP) reduces the diagnostic value of the procedure and may worsen the outcome of patients with acute lymphoblastic leukemia (ALL). Little is known about the risk factors for traumatic and bloody LP...
  56. ncbi request reprint Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions
    Bassem I Razzouk
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, and Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, USA
    Cancer 106:2495-502. 2006
    ..The prognostic significance of age among pediatric patients with acute myeloid leukemia (AML) was investigated...
  57. pmc Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1
    S Jeha
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:1406-9. 2009
    ..These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse...
  58. pmc Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia
    Deepa Bhojwani
    All authors St Jude Children s Research Hospital and Deepa Bhojwani, Jun J Yang, Hiroto Inaba, Jeffrey E Rubnitz, Monika L Metzger, Scott C Howard, Raul C Ribeiro, Sima Jeha, John T Sandlund, and Ching Hon Pui, University of Tennessee Health Sciences Center, College of Medicine, Memphis, TN
    J Clin Oncol 32:949-59. 2014
    ....
  59. ncbi request reprint Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia
    John T Sandlund
    Department of Hematology Oncology, St Jude Children s Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN 38105, USA
    Blood 100:43-7. 2002
    ....
  60. pmc Spinal epidural lipomatosis in children with hematologic malignancies
    Rachel C Brennan
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Ann Hematol 90:1067-74. 2011
    ..Investigation for SEL in leukemia or lymphoma patients with difficult lumbar punctures is warranted. Placement of an Ommaya reservoir may facilitate safe CNS-directed therapy in severely affected patients...
  61. ncbi request reprint Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma
    R C Ribeiro
    Department of Hematology-Oncology, St Jude Children's Research Hospital, 332 N, Lauderdale, Memphis, TN 38105-2794, USA
    Leukemia 15:891-7. 2001
    ..Therefore, the clinical usefulness of MR imaging as a screening tool for AVNB in this set of patients remains uncertain...
  62. ncbi request reprint Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience
    B I Razzouk
    Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38105-2794, USA
    Leukemia 15:1326-30. 2001
    ..They also suggest that dose intensification of etoposide and addition of 2-CDA may also offer an advantage. This study underscores the dependence of the prognostic impact of cytogenetic features on the efficacy of treatment...
  63. doi request reprint Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia
    Beth Kurt
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 113:376-82. 2008
    ..The aim of this study was to determine whether antibiotic prophylaxis during periods of neutropenia reduced streptococcal (S. viridans) sepsis and overall bacterial sepsis...
  64. doi request reprint Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 113:522-9. 2008
    ..To the authors' knowledge, no recently published study has evaluated the management and clinical course in this regard, especially in relation to pediatric patients...
  65. pmc Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia
    Shuiying Hu
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    J Natl Cancer Inst 103:893-905. 2011
    ..We investigated a treatment strategy combining sorafenib, a multikinase inhibitor with limited single-agent activity in AML, and cytarabine, a key component of AML chemotherapy...
  66. ncbi request reprint Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia
    Nobuko Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pediatr Blood Cancer 44:63-9. 2005
    ..Life-threatening pulmonary complications that coincide with cell lysis during early chemotherapy and that mimic systemic inflammatory response syndrome (SIRS) have been reported in patients with acute myeloid leukemia (AML)...
  67. ncbi request reprint Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience
    U H Athale
    Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA
    Blood 97:3727-32. 2001
    ..Allogeneic transplantation during remission offers the best chance of cure; in the absence of remission, transplantation offers no advantage over chemotherapy alone. (Blood. 2001;97:3727-3732)..
  68. ncbi request reprint Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience
    J E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 16:2072-7. 2002
    ..These results suggest that t(8;21)-positive AML represents a heterogeneous disease with variable outcome. The reported favorable outcome for t(8;21)-positive AML in other studies may be due to the use of high-dose cytarabine...
  69. ncbi request reprint Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience
    B L Abbott
    St Jude Children s Research Hospital, University of Tennessee, Memphis, TN 38105 2794, USA
    Leukemia 17:2090-6. 2003
    ..CNS involvement had no adverse prognostic significance, and patients with CNS2 status had similar outcome to CNS1 patients in this large group of pediatric patients with AML, treated at a single institution...
  70. pmc Inhibition of OCTN2-mediated transport of carnitine by etoposide
    Chaoxin Hu
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Mol Cancer Ther 11:921-9. 2012
    ..4-fold). Collectively, these findings indicate that etoposide can inhibit hOCTN2 function, potentially disturb carnitine homeostasis, and that this phenomenon can contribute to treatment-related toxicities...
  71. pmc Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukemia
    Pamela S Hinds
    Division of Nursing Research, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Eur J Oncol Nurs 13:156-63. 2009
    ..Our findings demonstrates the feasibility of measuring HRQoL in adolescents with OS or AML (and their parents) at the time of diagnosis, and thus their HRQoL ratings can be used to inform their cancer care from diagnosis forward...
  72. pmc Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia
    Davonna S Ledet
    Division of Neurology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Eur J Paediatr Neurol 14:78-9. 2010
    ..We report the successful use of levetiracetam monotherapy after Phenobarbital load in a neonate with leukemia and localization-related epilepsy...
  73. ncbi request reprint Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia
    C H Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 16:3768-73. 1998
    ..To reassess the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia (ALL)...
  74. ncbi request reprint Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse
    N Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 18:1581-6. 2004
    ..0+/-9.6% for those with late relapse and 20.0+/-8.0% for those with early relapse. We conclude that low-dose etoposide administered orally has a cytoreductive effect in relapsed ALL...
  75. ncbi request reprint Second malignancy after treatment of childhood acute myeloid leukemia
    W Leung
    Department of Hematology-Oncology, St Jude Children's Research Hospital, and University of Tennessee, College of Medicine, Memphis, USA
    Leukemia 15:41-5. 2001
    ..Future studies should focus on improving treatments for primary AML while preventing second malignancies...
  76. ncbi request reprint Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000
    R C Ribeiro
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 19:2125-9. 2005
    ..We conclude that subtype-specific therapies are needed to replace the 'one size fits all' strategy of the past two decades...
  77. ncbi request reprint Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia
    S C Howard
    Department of Hematology Oncology, ALSAC Bldg, Room C6005, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105 2794, USA
    JAMA 284:2222-4. 2000
    ..Patients with thrombocytopenia are at risk for spontaneous or procedure-related hemorrhage. Whether such patients can safely undergo lumbar puncture (LP) without prophylactic platelet transfusion is unknown...
  78. ncbi request reprint Late effects of treatment in survivors of childhood acute myeloid leukemia
    W Leung
    After Completion of Therapy Program, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 18:3273-9. 2000
    ..To investigate the incidence of and risk factors for late sequelae of treatment in patients who survived for more than 10 years after the diagnosis of childhood acute myeloid leukemia (AML)...
  79. ncbi request reprint Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia
    S Mathew
    Department of Pathology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Genes Chromosomes Cancer 28:227-32. 2000
    ..This report is the first to describe new partner breakpoints at 2p23 and 6p22 for MLL and CBFA2 genes, respectively, and concurrent rearrangements of these genes in a patient with secondary MDS...
  80. ncbi request reprint Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation
    N Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 19:1399-403. 2005
    ..In conclusion, the prognostic impact of overt testicular disease has diminished. Irradiation appears to provide no survival advantage to this patient population...
  81. ncbi request reprint Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia
    A Gajjar
    Departments of Hematology Oncology, Biostatistics and Epidemiology, Pharmaceutical Sciences, and Pathology, St Jude Children s Research Hospital, Memphis, TN, USA
    Blood 96:3381-4. 2000
    ..These data indicate that contamination of CSF with circulating leukemic blast cells during diagnostic lumbar puncture can adversely affect the treatment outcome of children with ALL and is an indication to intensify intrathecal therapy...
  82. ncbi request reprint Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse
    E Coustan-Smith
    Department of Hematology Oncology, Children s Research Hospital, Memphis, TN, USA
    Leukemia 18:499-504. 2004
    ..We conclude that MRD assays should be used to guide the selection of postremission therapy in patients with ALL in first relapse...
  83. pmc Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia
    C H Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 24:371-82. 2010
    ..The next main challenge is to further increase cure rates while improving quality of life for all patients...
  84. ncbi request reprint Second malignancy after treatment of childhood non-Hodgkin lymphoma
    W Leung
    St Jude Children s Research Hospital, 332 N Lauderdale Street, Memphis, TN 38105 2794, USA
    Cancer 92:1959-66. 2001
    ....
  85. pmc Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia
    Patrick K Campbell
    Division of Leukemia Lymphoma, St Jude Children s Research Hospital, Memphis, TN, USA
    Leuk Res 35:1321-9. 2011
    ..We also show a relatively high incidence of ABCG2 mRNA expression in non-Down associated M7 AML, which may contribute to the relatively poor prognosis of the M7 AML subtype...
  86. pmc Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia
    J G Blanco
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Proc Natl Acad Sci U S A 98:10338-43. 2001
    ..These data indicate that the malignant clone was not present before therapy, arose early during chemotherapy, and was able to proliferate even during exposure to antileukemic therapy...
  87. pmc Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia
    Ina Radtke
    Department of Pathology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Proc Natl Acad Sci U S A 106:12944-9. 2009
    ..These data reflect a remarkably low burden of genomic alterations within pediatric de novo AML, which is in stark contrast to most other human malignancies...
  88. pmc Isolated nasal septum necrosis caused by Aspergillus flavus in an immunocompromised child
    Fouzia Naeem
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN, USA
    Pediatr Infect Dis J 30:627-9. 2011
    ..With the increasing population of immunocompromised children, it is essential for timely management that clinicians have a high index of suspicion for this unusual presentation of aspergillosis...
  89. pmc Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia
    J R Roberson
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:245-50. 2009
    ..Pediatric patients with or without hyperglycemia during remission induction for ALL have similar clinical outcome. Occurrence of hyperglycemia does not warrant alteration of the antileukemic regimen...
  90. ncbi request reprint Urolithiasis in pediatric patients with acute lymphoblastic leukemia
    S C Howard
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 17:541-6. 2003
    ..05). Seven patients (35%) had recurrent urolithiasis. Patients with ALL are at risk of developing calcium renal stones during chemotherapy, especially when a glucocorticoid is included...
  91. pmc An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia
    Tanja A Gruber
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer Cell 22:683-97. 2012
    ..These data suggest that expression of CBFA2T3-GLIS2 directly contributes to leukemogenesis...
  92. pmc Childhood acute myeloid leukaemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Br J Haematol 159:259-76. 2012
    ....
  93. pmc Cutaneous infection caused by Macrophomina phaseolina in a child with acute myeloid leukemia
    Ashok Srinivasan
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, MS 260, Memphis, TN 38105, USA
    J Clin Microbiol 47:1969-72. 2009
    ..The fungus was identified by DNA sequencing using both the internal transcribed spacer and D1/D2 region of the 28S ribosomal DNA gene...
  94. pmc Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
    Kirk R Schultz
    Children s Oncology Group, Department of Pediatrics, BC Children s Hospital, University of British Columbia, Vancouver, Canada
    Blood 109:926-35. 2007
    ....
  95. ncbi request reprint TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches
    Mignon L Loh
    Department of Pediatric Hematology Oncology, University of California San Francisco, San Francisco, California 94143 0519, USA
    Curr Opin Hematol 9:345-52. 2002
    ..Incorporating knowledge of this gene rearrangement into treatment decisions serves as a paradigm for translating molecular discoveries into clinically meaningful data to direct patient care and improve outcome...